IAS 2015: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Conference Reports for NATAP


IAS 2015: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver, Canada 18-22 July 2015

	Bioequivalence of Two Dosage Strength Fixed-Dose Combination Formulations of Emtricitabine/Tenofovir Alafenamide (F/TAF) to Elvitegravir/Cobicistat/Emtricitabine/TAF (E/C/F/TAF) - (12/18/15) Aging/Comorbities at IAS http://www.natap.org/2015/HIV/081815_02.htm HCV Co-infection Report by David Shepp MD - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (09/02/15) HIV Prevention at IAS 2015 Vancouver - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (08/07/15) Antiretroviral Therapy at IAS Conference on Pathogenesis, Treatment and Prevention Vancouver, BC, Canada, July 19-22, 2015 - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (08/12/15) Fibrosis Regression is Possible after Successful Treatment of Hepatitis C, Even with Cirrhosis - Patients with F4 don't regress as often as those with earlier disease - (09/02/15) Efficacy and Safety of Switching to Simpler Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults in North America and Japan (NCT02071082): Week 48 Results - (08/16/15) The risk of cardiovascular disease and death over 10 years in HIV/HCV co-infected patients with and without steatosis ....mortality was high .....high rates of cardiovascular disease - (08/14/15) Relative Bioavailability of a Dolutegravir (DTG) Dispersible Tablet and the Effect of Low and High Mineral Content Water on the Tablet in Healthy Adult Volunteers - (08/12/15) Can the UNAIDS 90-90-90 target be achieved? Analysis of 12 national level HIV treatment cascades - (08/12/15) Prevention at IAS: (1) PrEP / (2) EARLY ART START Study - (3) Early ART (TaSP - Study HPTN052 in serodiscordant couples - Treatment as Prevention to prevent sexual transmission) - (08/12/15) Predicting Fractures by DEXA- new technique - (08/10/15) A Comparison of Daily and Non-daily Pre-exposure Prophylaxis Dosing in Thai Men Who Have Sex With Men, Bangkok - HPTN 067 / ADAPT Study - (08/07/15) HPTN 067/ADAPT Background and Methods and Cape Town Results: - (08/07/15) PrEP experiences among South African women in the HPTN067 (ADAPT) study: Healthy paranoia (skepticism), Ubuntu, champions and challenges to resolving PrEP dissonance...... - (08/07/15) HPTN 067/ADAPT: 'PrEP Ubuntu' and experiences with open-label PrEP among South African women - (08/07/15) Patterns of sex and PrEP in Bangkok MSM (HPTN 067/ADAPT Study) - (08/07/15) Characteristics and Oral PrEP Adherence in the TDF2 Open-Label Extension in Botswana - (08/07/15) HIV infection and vascular stiffness among older-adults taking antiretroviral therapy in rural Uganda.... arterial stiffness occurs more often in HIV+ .....aging/HIV in Africa - (08/06/15) Asymptomatic neurocognitive impairment (ANI) is associated with progression to symptomatic HIV-associated neurocognitive disorders (HAND) in people with HIV: results from The Ontario HIV Treatment Network (OHTN) cohort study..... - (08/06/15) Feasibility of Intermittent PrEP Among US MSM: Data from the Harlem Site - HPTN 067: ADAPT Study - (08/05/15) Treat HIV Early for Prevention (HPTN-052 TaSP) and for Treatment (START) - PrEP too - (08/05/15) Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs - (08/05/15) Patterns of Sex and PrEP in Harlem MSM: A qualitative study (HPTN 067) [Stigma/adherence/Sex] - (08/05/15) Adherence, sexual behavior and HIV/STI incidence among men who have sex with men (MSM) and transgender women (TGW) in the US PrEP demonstration (Demo) project - (08/04/15) Myocardial Strain Abnormalities Detected by Speckle-Tracking Echocardiography in Persons with HIV - (08/03/15) Heart Disease/Subclinical Heart Disease/Immune Activation/Inflammation....exercise, diet......."Squelching chronic inflammation with diet and exercise is in many ways a no-brainer" - (08/03/15) ATN 110: An HIV PrEP Demonstration Project and Safety Study for Young Men (18-22) who Have (high-risk) Sex with Men in the United States, in 12 cities.....successfully identified & engaged in project - (08/03/15) Pre-exposure prophylaxis (PrEP) uptake and associated factors among MSM and TGW in the PrEP Brasil demonstration project - (08/03/15) Evaluation and Management of Fracture Risk in HIV Patients in the VA system: .....Fractures - HIV+ Vets NO SCREENING/PREVENTION! ..... One Quarter of HIV+ Vets Have Recurrent Fracture--After Minimal Testing or Treatment - Mark Mascolini - (07/31/15) Over 80% of MSM Don't Discuss PrEP With Their Clinician--and Many Don't Talk About Sex - Mark Mascolini - (07/31/15) Favourable effects on vitamin D and bone of switching from Atripla to Darunavir/Ritonavir monotherapy: a randomised controlled clinical trial - (07/31/15) Switch from PI/rtv +2 nucleos(t)ides to RPV+DRV/rtv maintains HIV suppression and is well tolerated (PROBE study) - (07/31/15) Poor Bone Prevention/Care in VA - (07/31/15) TELOMERE LENGTH SHORTENING AND DNA METHYLATION DISRUPTIONS OCCUR EARLY FOLLOWING HIV SEROCONVERSION.... ......"This suggests that cellular aging and methylomic disruptions are likely to occur soon after contraction of HIV." - (07/31/15) Serious Non-AIDS Events and Biomarker Changes in HIV-1-Infected Individuals - Inflammation Markers & Comorbidities: higher markers in HIV+ with comorbidities - (07/31/15) ELICITING COGNITIVE DIFFICULTIES EXPERIENCED BY PEOPLE LIVING WITH HIV - (07/31/15) HCV/HIV Coinfection at IAS Vancouver 2015 July 19-23 - (07/30/15) No Hepatitis Flares When HBsAg+ iPrEx Participants Stop TDF/FTC - Mark Mascolini - (07/29/15) HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with Rifabutin, with or without Ritonavir, in Healthy Subjects - (07/29/15) Treat HCV Early or you are at risk of cirrhosis & then not achieving regression of fibrosis which increases death rate & liver-related complications.....study finds fibrosis regression is required even with an SVR to reduce all-cause death & liver-related death.....THUS, early HCV treatment is crucial, waiting until cirrhosis is tantamount to a 50% chance of a death sentence - (07/29/15) HIV Incidence Low, Despite High STI Rate, in US MSM in Big PrEP Demo Project - Mark Mascolini - (07/29/15) Hospitalizations among HIV Controllers versus Persons with Medically-Controlled HIV - Hospital Admission Rate Same for No-ART and ART HIV Controllers in US Military - Mark Mascolini - (07/29/15) Mortality Steady and Non-AIDS Deaths Rising in British Columbia Since 2005 - Mark Mascolini - (07/29/15) Private Insurance--and ADAP--Tied to Undetectable Viral Load in US Women - Mark Mascolini - (07/29/15) Aging, Hospitalization Rates for Liver/GI - Rates Increased for Cardiovascular Disease & Non-AIDS Cancers in Italy - Mark Mascolini - (07/29/15) ART Begun at Higher CD4 Count Tied to Lower Mortality in Vancouver IDUs - Mark Mascolini - (07/29/15) Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir - (07/28/15) Frequent Fibrosis Regression With SVR in HCV/HIV+, Cutting Death Risk - (07/28/15) Evaluation and Management of Fracture Risk in HIV Patients in the VA system: .....Fractures - HIV+ Vets NO SCREENING/PREVENTION! ..... One Quarter of HIV+ Vets Have Recurrent Fracture--After Minimal Testing or Treatment - (07/27/15) TLR7 Agonist GS-9620 is a Potent Inhibitor of Acute HIV-1 Infection in Human PBMCs - (07/27/15) PrEP at IAS Vancouver 2015 July 19-22.....Daily PrEP Appears Most Effective....more NATAP PrEP IAS Reports coming - (07/27/15) Feasibility of Intermittent PrEP Among US MSM: Data from the Harlem Site - HPTN 067: ADAPT Study - (07/27/15) Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men in the HPTN 067/ADAPT study - (07/27/15) PrEP, Sex, and the Paradoxes of Prevention: Qualitative data from a cohort of New York City MSM participating in HPTN 067/ADAPT [Harlem, NY, USA] - (07/27/15) New HIV Drugs at IAS 2015 Vancouver July 19-23 - (07/27/15) TLR7 Agonist GS-9620 is a Potent Inhibitor of Acute HIV-1 Infection in Human PBMCs - (07/27/15) Treatment as Prevention: Characterization of partner infections in the HIV Prevention Trials Network 052 trial - (07/27/15) Raltegravir for the prevention of mother-to-child transmission of HIV - (07/27/15) Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15) Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15) The HIV Continuum of Care for Adolescents and Young Adults (12-24 years) Attending 13 Urban US Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative .........Only 7% of Youth in US Study Reach an Undetectable Viral Load After HIV Diagnosis - Mark Mascolini - (07/24/15) Incidence of Syphilis, Other STIs Rising Steadily in HIV+ MSM of France - Mark Mascolini - (07/24/15) HIV Risk Dropped 65% in Seattle Area MSM Born After Mid-1960s - (07/24/15) HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Analysis of Emergent Viral Drug Resistance Through 48 Weeks of Follow-Up - (07/24/15) Safety and Efficacy of DTG by Age, Race and Gender: Subgroup Analysis of 96 Week Results From Treatment-Naive Patients in Phase III Trials (SPRING-2 [ING113086], SINGLE [ING114467] and FLAMINGO [ING114915]) - (07/24/15) Bone Mineral Density and Fat Distribution in Adults Randomized to Maraviroc (MVC) Once Daily With Darunavir/Ritonavir (DRV/r) vs. Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: Week 48 Results From MODERN - (07/24/15) START Trial: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection......The START trial was designed and conducted by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)..... - (07/24/15) Decrease in the proportion of HIV-positive MSM followed up in hospital likely to transmit HIV between 2003 and 2011 in France: results from national representative surveys (ANRS-VESPA1 and -VESPA2) - (07/24/15) STIs incidence in MSM followed since HIV-1 primary infection in the French ANRS-PRIMO cohort..... Does Undetectable Viral Load Influence Sex Behavior - (07/24/15) Women in Peril: High Levels of HIV Infection Risk among the Male Sex Partners of Low-Income, Black Women in the United States...... "Nearly 1 in 5 HIV-negative, black women included in our analysis had a male sex partner at high risk for HIV infection." - (07/24/15) Evolution of HIV-1 Integrase Following Selection of R263K With Further Dolutegravir Treatment: A Case Report From the P1093 Study - (07/24/15) Antiretroviral Treatment Prevents HIV Transmission: Final Results from the HPTN 052 Randomized Controlled Trial - (07/22/15) Early ART Cuts HIV Transmission Rate 93% Through 2015 in HPTN 052 - written by Mark Mascolini - (07/22/15) Cape Town Women Data Support Daily TDF/FTC PrEP Over As-Needed PrEP - written by Mark Mascolini - (07/22/15) Kidney and Bone Marker Rally After TDF-to-TAF Switch for 48 Weeks - written by Mark Mascolini - (07/22/15) (ACTG) Long-term Bone Mineral Density Changes in Antiretroviral-treated HIV-Infected Individuals, Bone Loss Continues--Though Slowly--After First 96 Weeks of ART - written by Mark Mascolini - (07/22/15) More Diabetes and CVD, Shorter Survival, in HIV/HCV-Positives With Steatosis - written by Mark Mascolini - (07/22/15) Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazanavir ± Ritonavir - (07/22/15) Switching From a Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to a Tenofovir Alafenamide (TAF)-Based Regimen: Data in Virologically Suppressed Adults Through 48 Weeks of Treatment - (07/22/15) Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112 - (07/22/15) Efficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results - (07/22/15) Strategic Timing of AntiRetroviral Treatment (START) Study Primary Results - (07/22/15) C-EDGE CO-INFECTED: Phase 3 Study of Grazoprevir / Elbasvir in Patients with HCV/HIV - (07/22/15) DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM (AI444-258) - (07/22/15) Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (07/22/15) Abbvie 3D in HCV/HIV Update ......HIGH SVR RATES IN HCV/HIV-1 CO-INFECTED PATIENTS REGARDLESS OF BASELINE CHARACTERISTICS........(note IDUs had 100% SVR) - (07/22/15) HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus - NIH HPTN 052 Study - (07/21/15) Early ART Stalls Viral Evolution in Infant But Does Not Stop Replication - written by Mark Mascolini - (07/21/15) Ipergay Analysis Suggests Both Pre- and Postsex TDF/FTC PrEP Doses Needed for Full Protection - written by Mark Mascolini - (07/21/15) Intensive Case Management Improves Engagement, HIV Control in Wisconsin Study - written by Mark Mascolini - (07/21/15) Shorter Treatment Breaks, More Regimens Predict Complete CD4 Response in 10 Years - written by Mark Mascolini - (07/21/15) Age, IDU, Viral Load Testing Rate Predict HIV Control and Rebound in Canadian MSM - written by Mark Mascolini - (07/21/15) Meth Use May Account for 1 in 5 of New HIV Infections in Seattle MSM - written by Mark Mascolini - (07/21/15) Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Is Superior to Ritonavir (RTV)-Boosted Atazanavir (ATV) Plus FTC/TDF in Treatment-Naïve Women With HIV-1 Infection (WAVES Study) - (07/20/15) HIV Self-Testing Raises Testing Rate in Randomized Trial of Seattle MSM - written by Mark Mascolini - (07/20/15) Rilpivirine 48-Week Results in Naive Adolescents Similar to Adult Findings - written by Mark Mascolini - (07/20/15) Stribild Superior to Boosted Atazanavir in Treatment-Naive Women - written by Mark Mascolini - (07/20/15) VAC-3S, a safe Immunotherapeutic HIV Vaccine decreased total HIV DNA and increased CD4/CD8 ratio: Phase I Final Results. - (07/20/15) A vaccine strategy against AIDS: An HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques - (07/20/15) VAC-3S, an Immunoprotective HIV Vaccine Directed to the 3S Motif of gp41, in Patients Receiving ART: Safety, Dose & Immunization Schedule Assessment - (07/20/15) VAC-3S HIV Therapeutic Vaccine - "Potential Role of anti-3S antibodies in an HIV medical cure strategy?" - (07/20/15) Therapeutic HIV Vaccine Boosts CD4/CD4 Ratio, Cuts HIV DNA in PBMCs in 33-Person Trial - written by Mark Mascolini - (07/20/15)